OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Metastatic Neoplasm reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,256 reports · 127 co-occurring drugs

As of the last recalculation, Metastatic Neoplasm appears in 4,256 FAERS reports alongside 127 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 15.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Ado-Trastuzumab Emtansine2715.815.8
Goserelin4014.714.7
Anastrozole Tablets5813.413.4
Anastrozole9212.512.5
Lapatinib3912.412.4
Fulvestrant8212.412.4
Pertuzumab6712.212.3
Trastuzumab16312.012.1
Capecitabine20911.711.7
Erlotinib Hydrochloride2710.610.6
Trametinib4910.010.0
Anti-Thymocyte Globulin (Rabbit)169.79.8
Erlotinib199.69.6
Irinotecan Hydrochloride249.29.2
Memantine238.38.3
Memantine Hydrochloride238.38.3
Dabrafenib358.28.2
Bevacizumab1978.18.1
Prochlorperazine Maleate158.08.0
Atezolizumab627.97.9
Gemcitabine617.77.7
Paclitaxel (Aibumin-Bound)1257.67.6
Everolimus Tablets267.67.6
Letrozole937.57.5
Apalutamide187.57.5
Carboplatin1877.57.5
Senna Leaf347.37.3
Exemestane317.17.1
Paclitaxel1387.07.0
Basiliximab166.76.7
Isosorbide Mononitrate286.66.6
Standardized Senna Concentrate176.66.6
Epoetin Alfa166.66.6
Abiraterone186.56.5
Bicalutamide206.46.5
Letrozole Tablets626.46.4
Sennosides 8.6 Mg Tablets276.36.3
Senna276.36.3
Gemcitabine Hydrochloride676.36.3
Cisplatin986.36.3
Docetaxel Anhydrous846.26.2
Docetaxel846.26.2
Pazopanib Hydrochloride346.26.2
Pemetrexed266.06.0
Leucovorin Calcium225.75.7
Olaparib245.65.6
Everolimus575.55.5
Vismodegib105.55.5
Sirolimus155.55.5
Ribociclib355.55.5
Magnesium Hydroxide155.55.5
Leuprolide Acetate855.45.5
Gefitinib105.45.4
Temozolomide235.45.4
Vemurafenib135.35.3
Oxaliplatin765.15.1
Alpelisib95.15.1
Fluorouracil Cream, 0.5%775.05.0
Fluorouracil785.05.0
Telmisartan184.95.0
Dronabinol84.94.9
Sennosides294.84.8
Pancrelipase374.74.7
Ifosfamide204.64.6
Pemetrexed Disodium354.54.5
Docusate Sodium 100Mg214.34.3
Regorafenib104.24.2
Clozapine1064.24.2
Etoposide624.24.2
Durvalumab174.14.1
Abiraterone Acetate333.93.9
Abemaciclib163.93.9
Prochlorperazine223.93.9
Niraparib173.83.8
Amlodipine Besylate And Benazepril Hydrochloride73.73.7
Raloxifene Hydrochloride113.73.7
Zoledronic Acid293.63.6
Thalidomide263.53.5
Loperamide Hydrochloride And Dimethicone223.43.4
Bleomycin Sulfate73.33.3
Darbepoetin Alfa363.33.3
Granisetron Hydrochloride73.33.3
Osimertinib213.23.2
Sitagliptin And Metformin Hydrochloride143.23.2
Imatinib Mesylate183.23.2
Erythropoietin133.13.1
Sorafenib133.13.1
Palbociclib593.13.1
Doxorubicin553.03.0
Doxorubicin Hydrochloride203.03.0
Encorafenib63.03.0
Denosumab1162.92.9
Cetuximab182.82.8
Panitumumab92.82.8
Venetoclax352.82.8
Trifluridine And Tipiracil62.72.7
Crizotinib72.72.7
Obinutuzumab92.72.7
Alteplase82.62.6
Cyclophosphamide Injection, Solution932.62.6
Cyclophosphamide932.62.6
Cyclophosphamide For Injection932.62.6
Romiplostim82.62.6
Ranibizumab142.62.6
Ravulizumab72.52.5
Lanreotide Acetate42.52.5
Sunitinib Malate202.52.5
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose42.42.4
Enzalutamide272.32.3
Exenatide242.22.2
Romosozumab-Aqqg62.22.2
Mirabegron172.22.2
Acalabrutinib52.02.0
Loratadine And Pseudoephedrine Sulfate31.81.8
Risankizumab-Rzaa291.71.7
Nivolumab341.71.7
Tafamidis41.71.7
Conjugated Estrogens And Medroxyprogesterone Acetate81.71.7
Lutetium Lu 177 Vipivotide Tetraxetan41.51.5
Fam-Trastuzumab Deruxtecan-Nxki31.51.5
Paricalcitol41.41.4
Ipilimumab121.41.4
Ixazomib81.41.4
Pegfilgrastim231.11.1
Aflibercept71.11.1
Ranitidine Hydrochloride100.90.9
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride50.80.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.